Stay updated on Paclitaxel and Pembrolizumab in Refractory Urothelial Cancer Clinical Trial
Sign up to get notified when there's something new on the Paclitaxel and Pembrolizumab in Refractory Urothelial Cancer Clinical Trial page.

Latest updates to the Paclitaxel and Pembrolizumab in Refractory Urothelial Cancer Clinical Trial page
- Check4 days agoNo Change Detected
- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedAdded a Locations section listing North Carolina as the study site; removed the previous North Carolina Locations entry and updated the footer to reflect the change.SummaryDifference0.2%

- Check26 days agoNo Change Detected
- Check40 days agoChange DetectedThe page shows a minor revision update from v3.3.1 to v3.3.2, with no changes to the study details or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check47 days agoChange DetectedPage revision updated from v3.2.0 to v3.3.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check55 days agoChange DetectedThe government funding/operating status banner has been removed from the page, removing ancillary status notices. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check69 days agoChange DetectedResults have been posted and the study status shows Completed, with enrollment and completion dates updated accordingly.SummaryDifference0.4%

- Check97 days agoChange DetectedMajor update: adds a government-status notice and the new software version v3.2.0, replaces the old v3.0.2.SummaryDifference3%

Stay in the know with updates to Paclitaxel and Pembrolizumab in Refractory Urothelial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Paclitaxel and Pembrolizumab in Refractory Urothelial Cancer Clinical Trial page.